Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814676 | 0.84 | CYP3A4 (0.46) | CYP3A4CYP2C9 | |
| SCHEMBL4885373 | 0.81 | CYP3A4 (0.36) | CYP3A4CYP2C9 | |
| SCHEMBL4884334 | 0.80 | NR1I2 (0.32) | — | |
| SCHEMBL1814419 | 0.78 | CYP3A4 (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL1818094 | 0.77 | CYP3A4 (0.36) | CYP3A4CYP2C9 | |
| SCHEMBL5838530 | 0.77 | CYP3A4 (0.39) | CYP3A4CYP2C9ADORA2B | |
| SCHEMBL6061289 | 0.76 | CYP3A4 (0.33) | CYP3A4CYP2C9 | |
| SCHEMBL1816294 | 0.75 | CYP3A4 (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL5838692 | 0.72 | CYP3A4 (0.33) | CYP3A4CYP2C9ADORA2B | |
| SCHEMBL7142034 | 0.65 | CYP3A4 (0.38) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | claimed |
| US-20060154954-A1 | Combinations and use of selected pharmaceutically active compounds | ALTANA PHARMA AG (DE) | 2006-07-13 | — | — | US | claimed |
| US-20050020637-A1 | Agents for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-01-27 | — | — | US | claimed |
| EP-1453493-A2 | REVERSIBLE PROTON PUMP INHIBITORS FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2004-09-08 | — | — | EP | claimed |
| WO-2003043614-A2 | REVERSIBLE PROTON PUMP INHIBITORS FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-05-30 | — | — | WO | claimed |
| US-20080102133-A1 | Oral Pharmaceutical Preparation for Proton Pump Antagonists | ALTANA PHARMA AG (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080050428-A1 | Oral Pharmaceutical Preparation Comprising a Proton Pump Antagonist and a Basic Excipient | ALTANA PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
| EP-1799211-A1 | ORAL PHARMACEUTICAL PREPARATION COMPRISING A PROTON PUMP ANTAGONIST AND A BASIC EXCIPIENT | Altana Pharma AG (DE) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799190-A1 | ORAL PHARMACEUTICAL PREPARATION FOR PROTON PUMP ANTAGONISTS | Altana Pharma AG (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-7141567-B2 | Polysubstituted imidazopyridines as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2006-11-28 | — | — | US | disclosed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | disclosed |
| US-20060204568-A1 | Oral pharmaceutical preparation for proton pump antagonists | ALTANA PHARMA AG (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20050020637-A1 | Agents for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | disclosed |
| US-20040214852-A1 | Polysubstituted imidazopyridines | ALTANA PHARMA AG (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1453493-A2 | REVERSIBLE PROTON PUMP INHIBITORS FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| EP-1332143-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA Pharma AG (DE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003043614-A2 | REVERSIBLE PROTON PUMP INHIBITORS FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002034749-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | GIPR, SLC10A2, VIP | CYP3A4 117/4885CYP2C9 821/4885ADORA2B 2082/4885 |
| US-20040214852-A1 | Polysubstituted imidazopyridines | GIPR, VIP, SLC10A2 | CYP3A4 38/4885CYP2C9 438/4885ADORA2B 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.